论文部分内容阅读
目的 :探讨分析英夫利昔单抗与硫唑嘌呤联用治疗克罗恩病的临床疗效。方法 :选取2015年1月至2017年1月在我院接受治疗的80例克罗恩病患者进行研究,将所有患者随机分为两组,每组40例,对照组予以英夫利昔单抗治疗,实验组予以英夫利昔单抗与硫唑嘌呤联用治疗,实验结束后,对两组患者治疗后ESR、CRP以及不良反应发生率进行比较分析。结果 :实验组患者治疗后ESR、CRP以及不良反应发生率明显低于对照组,P<0.05。结论 :英夫利昔单抗与硫唑嘌呤联用治疗克罗恩病的疗效显著,安全性较高,不良反应较少,值得临床推广应用。
Objective: To investigate the clinical efficacy of infliximab combined with azathioprine in the treatment of Crohn’s disease. Methods: From January 2015 to January 2017 in our hospital treated 80 cases of Crohn’s disease patients were studied, all patients were randomly divided into two groups, 40 cases in each group, the control group infliximab The experimental group was treated with infliximab and azathioprine. After the experiment, ESR, CRP and the incidence of adverse reactions were compared between the two groups after treatment. Results: The incidences of ESR, CRP and adverse reactions in the experimental group were significantly lower than those in the control group (P <0.05). Conclusion: The combination of infliximab and azathioprine treatment of Crohn’s disease has a significant effect, high safety and few adverse reactions, which is worthy of clinical application.